RxDoctor Payments Data

Joseph Binns, MD

Gastroenterology · Red Bank, NJNPI 1326049511

Payments from drug & device makers

$13,573in general payments, 2019–2025

Across 408 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$6K
  • AbbVie$2K
  • Johnson & Johnson$974
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$873
  • Pfizer$471
  • Ferring Pharmaceuticals Inc.$322
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$200%
  • Grants$200%
  • Food & beverage$7,84858%
  • Other$5,68542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,573 in reported general payments places this provider in the 85th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$155,650
Medicare patients
771
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$390,368
LinzessLinaclotide41$36,027
CreonLipase/Protease/Amylase14$35,507
TrulancePlecanatide11$14,188
ViberziEluxadoline13$10,012
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates123$8,090
Esomeprazole Magnesium172$7,607
Mesalamine23$6,816
Dexlansoprazole DrDexlansoprazole21$6,421
Omeprazole497$6,346
MotegrityPrucalopride Succinate12$5,652
Pantoprazole Sodium366$5,535
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,525
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag20$2,373
Mesalamine ErMesalamine14$1,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$974$390,36815 claims
AbbVieLinzess, Creon, Viberzi$2,084$81,54568 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$873$14,18811 claims
Braintree Laboratories, Inc.Sutab, Suflave$133$5,89942 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$303$5,65212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Red Bank

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →